United Kingdom
Literature review analyses cannabinoid system interactions in metastatic melanoma patients
This literature review examined the interactions between the endocannabinoid system, the gut microbiome, and metastatic melanoma patients receiving immunotherapy. It highlights the therapeutic potential of non-psychoactive cannabinoids like cannabidiol and cannabigerol as adjuncts to chemotherapy. However, research remains limited by historical regulatory barriers and the psychoactive properties of certain cannabis compounds.
- Cannabinoids are being investigated as potential adjunct therapies alongside standard melanoma treatments to overcome resistance.
- Non-psychoactive compounds such as cannabidiol and cannabigerol represent key areas for future clinical research.
- The 2018 rescheduling of cannabis-based medicines in the United Kingdom has facilitated wider pharmacological investigation.
Our view
The preclinical case for cytotoxic activity is long established; the clinical case is not yet made. What makes this review useful is its focus on non-psychoactive compounds such as CBD and CBG, where the regulatory and tolerability obstacles are lower, and on the microbiome as a mediating factor in patients receiving immunotherapy. None of it should be read as support for cannabinoids as a cancer treatment. It is a research agenda, not a therapy.
Sources
Get the latest medical cannabis news by email
We send AMI updates and research summaries once a week.
